Reclaiming Control: Ibrutinib Therapy for Relapsed Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is an aggressive blood cancer. Relapsing after initial chemotherapy is a harsh reality for many patients. Traditional treatments often lose their effectiveness quickly. The disease returns rapidly. This leaves patients and oncologists searching for viable second-line options. Time and clinical efficacy are critical. Ibrutinib offers a highly targeted approach. It specifically …
